Drugs / SYS6090
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07472647 | Feb 2026 → Feb 2029 expected | non-small cell lung carcinoma, small cell lung carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-08-26 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6090 (JMT108) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MSS/pMMR mCRC irasia.com ↗
SYS6090 (JMT108) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MSS/pMMR mCRC |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-08-26 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYS6090 (JMT108) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MSS/pMMR mCRC irasia.com ↗ |
| 2026-08-19 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE IB/II CLINICAL TRIAL OF SYS6090 INJECTION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA irasia.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6090 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07472647 ↗ |